You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Colorcon
Harvard Business School
Baxter
Johnson and Johnson

Last Updated: November 30, 2020

DrugPatentWatch Database Preview

Litigation Details for IN RE ASACOL ANTITRUST LITIGATION (D. Mass. 2015)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in IN RE ASACOL ANTITRUST LITIGATION
The small molecule drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for IN RE ASACOL ANTITRUST LITIGATION (D. Mass. 2015)

Date Filed Document No. Description Snippet Link To Document
2015-06-22 1 Complaint on Delzicol® is covered by U.S. Patent No. 6,649,180 (“the ‘180 patent”), which expires April 13, 2020…drug sales due to patent expiration has become known as the “patent cliff.” The patent cliff represents…“the ‘170 patent”) and 5,541,171 (“the ‘171 patent”). Both patents expired July 30, 2013. 34…equivalents, and any patents that purportedly protect each drug. 12. Drug patents typically last…which the patent issues and ending 20 years from the date on which the application for the patent was filed External link to document
2016-07-20 110 Memorandum & ORDER 11. The Orange Book lists U.S. Patent No. 6,649,180 (“the ’180 patent”) for Delzicol, which expires on…Orange Book lists two patents for Asacol, U.S. Patent Nos. 5,541,170 (“the ’170 patent”) and 5,541,171 (… (“the ’171 patent”). Id. ¶ 67. Both patents expired July 30, 2013. Id. In May 2008, the FDA approved…. ¶ 73. The Orange Book lists two patents for Asacol HD, U.S. Patent Nos. 6,893,662 and 8,580,302. Id…applicable patents are invalid or will not be infringed by the proposed generic drug. Id. If the patent owner External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Colorcon
McKinsey
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.